Navigation Links
Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay
Date:10/26/2008

ne at the David Geffen School of Medicine at UCLA. "Improving our ability to select the best therapy for patients is critical. These new data enhance the confidence that physicians need when making treatment choices."

Conference Call

Monogram will host a conference call Monday, October 27 at 4:30 p.m. Eastern Time, in which Dr. David Hardy will review the clinical use of Selzentry and Trofile. This call will be in conjunction with Monogram's third quarter conference call. Dr. Hardy is Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and is Associate Professor of Medicine at the David Geffen School of Medicine at UCLA. To participate in the live teleconference please call (877) 604-9672, or (719) 325-4896 for international callers, fifteen minutes before the conference begins. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Access to live and archived audio of the conference call will be available by following the appropriate links at http://www.monogrambio.com and clicking on the Investor Relations link. Following the live broadcast, a replay of the call will also be available at (888) 203-1112, or (719) 457-0820 for international callers. The replay passcode is 4461917. The information provided on the teleconference is only accurate at the time of the conference call, and Monogram assumes no obligation to provide updated information except as required by law.

About Trofile

Trofile is a clinically validated patient selection tropism assay that determines whether a patient is infected with a strain of HIV that uses either the CCR5 coreceptor, the CXCR4 coreceptor, or a combination of CCR5 and CXCR4 to enter cells. The use of CCR5, CXCR4 or both coreceptors defines the "tropism" of the virus strain. Trofile amplifies the envelope gene from a patient's H
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
2. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
3. Supportive Oncology Services Accrues One Million Cancer Patient Self-Reported Assessments
4. RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial
5. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
6. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
7. New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
8. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
9. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
10. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
11. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... directors of Eli Lilly and Company (NYSE: ... quarter of 2010 of $0.49 a share on outstanding ... March 10, 2010 to shareholders of record at the ... ,, Lilly, a leading innovation-driven corporation, is developing a ... research from its own worldwide laboratories and from collaborations ...
(Date:12/14/2009)... -- Cardinal Health today announced that executives of the ... Goldman Sachs CEO Unplugged Conference on ... Conference Center in New York. 28th Annual ... Noon EST at the Westin St. Francis Hotel in ... will discuss Cardinal Health,s diverse products and services, company ...
(Date:12/14/2009)... Conn., Dec. 14 Zargis Medical Corp., ... SPDE ) and a spin-off from Siemens Corporate ... that it has begun selling its award-winning Zargis ... ,, Cardioscan and its accompanying Bluetooth®-enabled electronic stethoscope ... "2009 Innovation of the Year." ...
Breaking Medicine Technology:Cardinal Health Executives to Speak at Two Investor Events in January 2Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 1Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 2Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 3Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 4Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 5eDiets com Selects Karlin+Pimsler to Lead Creative Turnaround 56017 1eDiets com Selects Karlin+Pimsler to Lead Creative Turnaround 56017 2MDS Announces Voting Support Agreements 56014 1MDS Announces Voting Support Agreements 56014 2MDS Announces Voting Support Agreements 56014 3
(Date:12/14/2009)... NEW YORK, Dec. 14 /PRNewswire-USNewswire/ -- The ... the largest survey on teen drug abuse tracking over ... teens, intentional abuse of prescription (Rx) and over-the-counter (OTC) ... an alarming number of young people abusing medicines they ... Teen Abuse of Medication Continues to Be a Pervasive ...
(Date:12/14/2009)... Grubb & Ellis Healthcare REIT II, Inc. announced ... distribution to stockholders of record as of the close of ... 1, 2010 and ending on Feb. 28, 2010. The ... calendar year and will be equal to an annualized distribution ... per share. These distributions will be aggregated and paid ...
(Date:12/14/2009)... Dec. 14 On December 9, 2009, the ... federal government,s position that private insurance companies are "plans" ... ,, Although other federal courts have held that contracts ... jurisdiction under Title 18 Section 1347, US vs. ... itself has been held to be a "plan," because, ...
(Date:12/14/2009)... had been treated, hadn,t spread, study finds , , MONDAY, ... the risk of death in male colon cancer survivors, ... 1986, included 668 men who,d been treated for stage ... had not spread (nonmetastatic cancer). Every two years, the ... new cancer and disease diagnoses, as well as their ...
(Date:12/14/2009)... shouldn,t worry most users, researcher says , , MONDAY, Dec. ... may have a small but statistically significant increased risk ... the medications, a new study finds. , "But statistical ... Jordan W. Smoller, an associate professor of psychiatry at ... in the Dec. 14 issue of Archives of ...
Breaking Medicine News(10 mins):Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Insurance Now Subject to Federal Jurisdiction 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3
... Hydra Booster Concentrated Conditioner Fortifies Water with Naturally Occurring Electromagnetic ... Balance , ... Los Angeles, CA ... a sea of bottled water, sports drinks, energy beverages and ...
... AMN Healthcare announced today that,it has been ... Organizations and continues to earn the Commission,s Gold ... now includes its,allied division: Med Travelers., AMN ... to be certified under,the Joint Commission,s corporate certification, ...
... The dog days of summer are here, and,for ... -- allergies. With an,estimated 40 percent of children and ... the rise. Americans are spending three billion,dollars a year ... their symptoms. Doctors say in-vitro blood tests, the,latest generation ...
... Anxiety is a normal human response to stress, but ... of excessive and irrational fears, such as obsessive-compulsive disorder, ... are available and can involve either behavioral therapy or ... these two treatments would result in even better results," ...
... Health, a,leading national provider of individual medical, ... that Jennifer Kopps-Wagner has been,named Senior Vice ... Kopps-Wagner joined Assurant Health in 1999, holding ... department. In her most recent role as,Vice ...
... Enhance Patient Safety and,Reduce Healthcare Costs, BETHESDA, ... nation,s first and only nationwide data collection program ... for a fall,2008 launch of its pilot. The ... donations, including an $84,000 contribution by Fenwal Inc., ...
Other Medicine News:Health News:Hydra Booster Energizes Ordinary Drinking Water for Better Absorption and Optimum Hydration, Stopping Symptoms of 'Hidden' Dehydration 2Health News:Hydra Booster Energizes Ordinary Drinking Water for Better Absorption and Optimum Hydration, Stopping Symptoms of 'Hidden' Dehydration 3Health News:Hydra Booster Energizes Ordinary Drinking Water for Better Absorption and Optimum Hydration, Stopping Symptoms of 'Hidden' Dehydration 4Health News:Hydra Booster Energizes Ordinary Drinking Water for Better Absorption and Optimum Hydration, Stopping Symptoms of 'Hidden' Dehydration 5Health News:AMN Healthcare Announces Joint Commission Re-Certification 2Health News:D-cycloserine may improve behavioral therapy treatment for anxiety 2Health News:Assurant Health Names Jennifer Kopps-Wagner Senior Vice President and General Counsel 2Health News:First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch 2Health News:First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch 3Health News:First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch 4Health News:First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch 5
Swing-Arm™ Scatter Shield® provides lower extremity protection for personnel close to the tube. 24"Wx32"L lead shield swings 180 along table. Ideal for cardiac cath, special studies, electr...
Ball-and-socket center mount can rotate 360, allowing them to be turned hoirzontally, vertically, or at any angle. Very versatile! Available with or without torso placement contour cutout and in thre...
... Primarily designed to prevent lower body exposure ... used on any table where X-ray fluoroscopy is ... protection in applications where C-arm fluoroscopy units are ... are offered, each equipped with a 17 cm ...
Economy Apron, Excellent Protection, Value Priced...
Medicine Products: